Greenwich LifeSciences, Inc. (GLSI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Greenwich LifeSciences, Inc. (GLSI) closed at USD 15.32 on 2026-10-15, a change of +67.4 % over the past year, with a market capitalization of USD 213.57M.

Greenwich LifeSciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Greenwich LifeSciences, Inc. key figures

Previous close

USD 15.32 (2026-10-15)

1-year change

+67.4 %

Market cap

USD 213.57M

Enterprise value

USD 204.69M

P/E ratio (trailing)

-9.51

P/E ratio (forward)

-17.74

EPS (trailing)

-1.53

EPS (forward)

-0.82

PEG ratio

n/a

Price to book

68.63

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.74

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Greenwich LifeSciences, Inc. and compare it with other stocks.